AGN News 142.00 04/21/2014 19:53:37 Allergan Inc (AGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Allergan Inc (AGN) 142.00 $AGN

Pershing Square and Valeant's Allergan Deal a Watershed for Activism
at The Street - 43 mins ago
Pershing Square Capital Management may be re-writing the rules of activist investing after teaming up with Valeant Pharmaceuticals on a potential takeover of Allergan.

Roche Launches Kadcyla in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 53 mins ago
Roche's breast cancer franchise received a boost when it announced that it has launched its cancer drug Kadcyla in Japan.

NYSE stocks posting largest percentage increases
AP - 2 hrs 50 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:

Stocks Rise; Valeant, Netflix Soar After Hours
at Investor's Business Daily - Mon Apr 21, 4:00PM CDT
Stocks rose Monday, with the S&P 500 notching its fifth straight gain, as quarterly earnings reports continue to roll out. Valeant Pharmaceuticals (VRX) soared in post-session trading after The Wall Street Journal reported that the Canadian drugmaker...

Why Allergan (AGN) Soared After Hoursin After Market Trading Today
at The Street - Mon Apr 21, 3:42PM CDT
Allergan (AGN) soared in after-hours trading on Monday amid news that activist investor William Ackman and Valeant Pharmaceuticals International have joined forces to pursue a takeover of the health care company. Ackman is the founder and CEO of...

SmarTrend Watching for Potential Pullback in Shares of Allergan After 6.03% Gain
Comtex SmarTrend(R) - Mon Apr 21, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $134.10 to a high of $142.00. Yesterday, the shares gained 6.0%, which took the trading range above the 3-day high of $134.41 on volume of 9.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

AGN June 21st Options Begin Trading
at The Street - Mon Apr 21, 10:52AM CDT
Investors in Allergan, Inc saw new options become available today, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGN options chain for the new June 21st contracts and identified one put and...

Next Resistance Level for Allergan (AGN) is $137.72
Comtex SmarTrend(R) - Mon Apr 21, 9:42AM CDT
Shares of Allergan (AMEX:AGN) opened today above their pivot of $132.51 and have already reached the first level of resistance at $135.82. Analysts will be watching for a cross of the next upside pivot targets of $137.72 and $142.93.

Glaxo Looking into Misconduct Charges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:35PM CDT
GlaxoSmithKline recently responded to investigations and charges of misconduct in Jordan and Lebanon.

Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.

Dr. Rian A. Maercks Announces Appointment to Elite ASCENT National Advisory Panel in Plastic Surgery, Comprised of Top 25 Leaders in Innovative Plastic Surgery in the U.S.
PR Newswire - Thu Apr 17, 7:45AM CDT
In recognition of expertise and interest in delivering the most innovative aesthetically superior treatment options, Dr. Rian A. Maercks has been appointed to the elite Allergan ASCENT advisory board of the top 25 leaders in plastic surgery in the U.S.

TauTona Group Sells Aline HA(R) to Allergan
Marketwire - Thu Apr 17, 7:30AM CDT
TauTona Group, a medical device incubator and investment fund focused on the rapid development of innovative medical products, today announced that its wholly-owned subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc. The Aline HA technology is under development for use as a dermal filler.

Stocks On Track For Third Gain; Allergan Rises
at Investor's Business Daily - Wed Apr 16, 1:54PM CDT
Stocks continued to hold near their session highs Wednesday afternoon and had little reaction to the Fed's beige book. The Dow Jones industrial average and the Nasdaq rose 0.8% each, while the S&P 500 climbed 0.7%. All three were on pace for a third...

Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.

Trade-Ideas: Allergan (AGN) Is Today's Momo Momentum Stock
at The Street - Wed Apr 16, 8:46AM CDT
Trade-Ideas LLC identified Allergan (AGN) as a momo momentum candidate

Another Earnings Beat from J&J, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 1:17PM CDT
J&J's earnings streak continues with the company reporting strong first quarter results and raising its guidance for the year.

Top-of-Mind Companies in Facial Injectable and Laser/Energy Device Markets Are Similar in Europe and Asia
PR Newswire - Tue Apr 15, 9:00AM CDT
Decision Resources Group, in collaboration with IMCAS (International Master Course on Aging Skin), finds that the top-of-mind companies in each of the botulinum toxin (BTX), dermal filler and laser/energy device markets are similar in Europe and in Asia. Not surprisingly, Allergan's BOTOX Cosmetic continues to be the top-of-mind BTX brand in both Asia and Europe, with Allergan's JUVEDERM and Galderma's Restylane both having high recognition among dermal filler brands. Lumenis came out on top for laser/energy devices in both regions.

3 Big-Volume Stocks in Breakout Territory
at The Street - Tue Apr 15, 7:23AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.

Global Retinal Vein Occlusion Therapeutics Pipeline Review 2014 - Analysis of 5 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jr9qs5/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Retinal Vein Occlusion - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV Drug Profiles - fluocinolone acetonide - beclomethasone dipropionate - ranibizumab - ocriplasmin - NCX-434 - NCX-422 For more information visit http://www.researchandmarkets.com/research/jr...tinal_vein

After Yesterday's Rally of 2.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 14, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $120.72 to a high of $124.46. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $121.96 on volume of 7.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 47

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 34

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Market Sentiment: Is APA Corp in a Bullish Phase?

Updated Category News Views 154

Understanding APA Corp's Short Interest Dynamics APA Corp's (NYSE: APA) stock has been under the microscope recently as its short interest, a key indicator for traders, has experienced a notable decline of 13.7%. This brings the total number of shares sold short to approximately 33.81 million, representing about 10.77% of all shares available for trading. Based on the...

Continue Reading
Market Insights: Oil Prices Rise While BioVie Shares Drop

Updated Category News Views 113

Market Overview In recent trading sessions, U.S. stocks showed varied performances. While the Dow Jones index experienced a slight drop, other indices like NASDAQ and S&P 500 managed to post modest gains. Stock Performance The Dow Jones fell by 0.04%, closing at 42,109.03. In contrast, the NASDAQ increased by 0.51%, finishing at 18,065.98, and the S&P 500 also climbed by...

Continue Reading
NTG Nordic Transport Group Adjusts Shareholding Structure

Updated Category News Views 242

NTG Nordic Transport Group Announces Shareholding Reduction In an important announcement, NTG Nordic Transport Group A/S (“NTG”) has updated its shareholders regarding its treasury shares following a strategic acquisition. The company reported that as of January 10, 2025, it owns 954,723 treasury shares, equivalent to a nominal value of DKK 20 each, totaling to a...

Continue Reading
Understanding Sydbank A/S Buyback Initiatives and Trends

Updated Category News Views 217

Insights into Sydbank A/S Share Buyback Program Welcome to an exploration of the recent developments surrounding the share buyback program initiated by Sydbank A/S. This financial strategy serves as a key indicator of the health and direction of the company. What is the Share Buyback Program? Recently, Sydbank A/S rolled out a share buyback initiative set at DKK 1,350...

Continue Reading
Governor Whitmer's Initiative to Enhance Education for Young Men

Updated Category News Views 129

Governor Whitmer Enhances Educational Opportunities for Young Men In a significant move aimed at supporting young men's access to education, Governor Gretchen Whitmer of Michigan has announced an executive directive that focuses on skills training and higher education enrollment. This initiative underscores the state’s commitment to educational and economic...

Continue Reading